You are on page 1of 4

JMSCR Vol||05||Issue||06||Page 22901-22904||June 2017
Impact Factor 5.84
Index Copernicus Value: 83.27
ISSN (e)-2347-176x ISSN (p) 2455-0450

Study of Patients with Non Alcoholic Fatty Liver Disease and its Association
with Metabolic Syndrome in tertiary centre
Dr P.Asati , Dr P.Kukrele2, Dr Sarita Jalodiya3
Asst. Professor, DM Gastroenterology, Dept of Medicine NSCB MCH Jabalpur
Asst. Professor, MD Medicine, Dept. of Medicine NSCB MCH Jabalpur
Junior Resident, MD Medicine, Dept. of Medicine NSCB MCH Jabalpur
NAFLD Nonalcoholic fatty liver disease (NAFLD) is emerging as an important cause of liver disease in India.
NAFLD includes patient with simple steatosis, as also those with non alcoholic steatoheaptitis (NASH). NASH
is more advanced stage of NAFLD and has a higher risk of progressing to liver cirrhosis or hepato cellular
carcinoma[1].NAFLD frequently associated with metabolic syndrome, obesity, Type-2 diabetes mellitus and
hyper lipidaemia are co-existing conditions frequently associated with NAFLD. Because of the strong
association with various metabolic abnormalitites, NAFLD is now considered as a part of spectrum of
metabolic syndrome. the present study is aimed to evaluate the clinical, biochemical profile in patients of
NAFLD with varying degree of severity as diagnosed by ultrasonography and evaluate the association
between the non-alcoholic fatty liver disease and the metabolic syndrome and its individual components as
defined by the NCEP ATP III criteria.
Results:51% of patients with NAFLD had metabolic syndrome and statistically significance was found in
AST, waist circumference, lipid profile total cholesterol was significantly higher in grade III NAFLD which
was significantly higher. AST ALT values were significantly higher among grade III NAFLD Cases (p value
<0.001,<0.001 respectively.

Introduction measure cause of liver related morbidity and

Non alcoholic fatty liver disease is most common mortality. Studies introduced that NAFLD may
liver disease since its prevalence is estimated to be progress to liver failure, cirrhosis and HCC
20% to 30% in general population of western (hepatocellular carcinoma)1. Available data from
countries1. NAFLD occurs as a histological clinical, experimental & epidemiological indicates
spectrum of disease and it include the subtypes of that NAFLD may be the hepatic manifestation of
simple steatosis and non alcoholic steatohepatitis metabolic syndrome4.
(NASH). NASH that is characterized by hepatic In 2001 the NCEP ATP III introduced simple
steatosis, liver cell injury, hepatic inflammation, clinical criteria which was widely adapted since
fibrosis, necrosis is believed to be an intermediate they are simple to use in clinical practice and
stage of NAFLD2.It was thought to be an benign since a large number of studies evaluated their
condition but is now increasingly recognized as a reliability5.

Dr P.Asati et al JMSCR Volume 05 Issue 06 June 2017 Page 22901

JMSCR Vol||05||Issue||06||Page 22901-22904||June 2017
In 2005 the American heart association (AHA) All patients diagnosed as NAFLD by
and the national lung heart and blood institute abdominal ultrasonography.
updated the ATP III criteria with minor Age >18years.
modifications. Thus, the metabolic syndrome is Exclusion criteria
defined by presence of three or more of the Patients <18 year or >85year of age.
following components 6: Patients with history of alcohol intake
Abdominal obesity (waist circumference >30gm /day in males &> 20gm /day in
>102cm in men and >88cm in women). females.
Elevated triglycerides (>150mg/dl or on Patient with history of jaundice or
drug treatment for elevated triglycerides). HbsAg/anti HCV positive.
Reduced HDL-C level (<40mg/dl in men Thyroid disorders
and<50mg/dl in women or on drug Patients with history of following drug
treatment for reduced HDL-C.) intake -steroids, synthetic estrogens, heap-
Hypertension (SBP >130mmhg or DBP rin, calcium channel blockers, amiodarone,
>85mmhg or on antihypertensive drug valproic acid, antiviral agents.7
treatment). Subjects were included in the study according to
Impaired fasting glucose (100-125mg/dl or the standard criteria accepted by the American
on antidiabetic drug treatment.) gastroenterology association i.e. an increase in
The frequent association of non alcoholic fatty hepatic echogenicity as a reference, had showed a
liver disease with individual component of the prevalence of 24.5%. The presence of enhance-
metabolic syndrome is now well known. However ement and lack of differentiation in the periportal
it is unknown whether the risk for this disease is intensity and the vascular wall due to great hyper
increased in patients with metabolic syndrome. echogenicity in the parenchyma8. There are three
This is important because the metabolic syndrome grades of fatty liver according to ultrasonographic
is an emerging problem worldwide and its finding:-
prevalence is likely increasing. Grade I- Slight diffuse increase in the fine echoes
This work was design to study the clinical profile liver appears bright as compared to the cortex of
of patients of non alcoholic fatty liver disease with kidney. Normal visualization of diaphragm and
varying degree of severity as diagnosed by intrahepatic vessel borders.
ultrasonography and evaluate the relationship Grade II- moderate diffuse increase in the fine
between NAFLD and metabolic syndrome along echoes slightly impaired visualization of
with its components as defined by the modified intrahepatic vessels and diaphragm.
NCEP ATP III criteria. Grade III- marked increase in the fine echoes.
poor or no visualization of intrahepatic vessel
Material and methods borders ,diaphragm and the vessel.
Ethics- The study was approved by the ethical
committee of N.S.C.B. MCH Jabalpur. Patients Results
was enrolled in study after written informed In our study out of 100 cases 68%, 28%, 5% cases
consent. are of grade I, grade II and grade III fatty liver
The study was an observational study of patients respectively. mean age is 47.0711.95 in yrs.
suspected as NAFLD attending OPD, and patients maximum no. of patients were in 4th& 5th decades
and male to female ratio was 5:4. According to
admitted in department of medicine NSCB
BMI 25% of patient were overweight, 61% were
Medical college, Jabalpur (M.P.) obese out of which 46% were moderately obese
Inclusion criteria and 15% were severly obese (BMI >30).

Dr P.Asati et al JMSCR Volume 05 Issue 06 June 2017 Page 22902

JMSCR Vol||05||Issue||06||Page 22901-22904||June 2017
Table 1: Comparison of variables in patients of Table 3 Comparision of variables of NCEP ATP
NAFLD, with and without metabolic syndrome III criteria in patients of NAFLD with metabolic
syndrome and NAFLD without metabolic
NAFLD with Metabolic syndrome NAFLD without Metabolic syndrome
Variables p value
Mean S D Mean S D
Fasting Sugar(mg/dl)) 128.18 5 9 . 3 1 97.57 2 7 . 6 2 0.001
SBP in (mmHg) 130.94 1 7 . 3 2 122.88 1 7 . 1 4 0.021
DBP (mmHg) 82.43 8 . 1 2 78.20 8 . 3 6 0.012
Triglyceride (mg/dl) 195.29 9 5 . 7 2 160.19 6 4 . 7 3 0.035
HDL (mg/dl) 39.12 5 . 9 1 44.10 8 . 0 7 0.001
Waist circumference (cm) 91.90 9 . 1 6 81.94 9 . 3 1 <0.001

In this study 100 subjects with NAFLD were
included out of which 51(51%) of NAFLD cases
had metabolic syndrome according to NCEP ATP
III Criteria using Asian indian standards for waist
circumference, Which was similar to studies of
Ajay Duseja et. al (50%)&Deepa Uchida et. al
(47%) .(9,10)
Out of 51 patients 31(60.7%), 20 (39.2%) were
Table 2:-Clinical and biochemical profile of all female and male respectively ,but statistically
cases of NAFLD was not significant when compared to NAFLD
V a r i a b l e M e a n Std. Deviation
cases not having metabolic syndrome. 67% were
Age (yrs) 47.07 1 1 . 9 5
SBP (mmHg) 126.99 1 7 . 6 2
female in a study conducted by Ajay Duseja et al.9
DBP (mmHg) 80.36 8 . 4 7 Mean age group of those having metabolic
Hb (gm/dl) 12.050 1 . 7 7 syndrome was 47.0711.9 which is higher by a
Total count (in cc) 662 3. 34 9 7889.20 decade to that reported by al (40.11+1.1)9
Fasting Sugar (mg/dl) 113.18 4 8 . 8 2 38% of those having metabolic syndrome had
PP sugar (mg/dl) 193.83 9 4 . 6 0 increased waist circumference (male >90cm,
Serum Bilirubin (mg/dl) . 9 3 6 0 . 3 4
Female >80cm.) which was statistically
ALT (IU/dl ) 57.51 5 2 . 1 0
AST (IU/dl) 46.48 2 7 . 3 0 significant. 58.7% and 47.1% of cases had
Total Cholesterol (mg/dl) 201.69 4 6 . 8 7 increased waist circumference as reported by
Triglyceride (mg/dl) 178.09 8 3 . 4 8 Bajaj et al and Ajay Duseja et al respectively.
HDL (mg/dl) 41.56 7 . 4 5 Hypercholestrolemia was seen in 46.4% of
LDL (mg/dl) 119.66 3 1 . 1 1 patients, hypertriglyceridemia seen in 83.48%
V L D L ( m g / dl ) 30.496 1 0 . 3 3
patients. 95.7%of NAFLD with metabolic
syndrome had Hypertriglyceridemia. In study of
Bajaj et al and deepauchil et al reported 23.1
&43.6%of patients with metabolic syndrome had
hypercholesterolemia and hypertriglyc-eridemia
In our study the p value for hypercholesterolemia
and Hypertriglyceridemia in grade III NAFLD

Dr P.Asati et al JMSCR Volume 05 Issue 06 June 2017 Page 22903

JMSCR Vol||05||Issue||06||Page 22901-22904||June 2017
Cases was <0.001, <0.006 which was significantly of the metabolic syndrome. diabetes
higher. 2001Aug ; 50 (8): 1844-1850.
Derranged AST (57.152.10) and ALT 5. Third report of the National Cholesterol
(40.4827.30) was found in greater %of patients Education Programme (NCEP) Expert
of NAFLD with metabolic syndrome than those panel on Detection Evaluation and Treat-
without metabolic syndrome with (p value <0.001, ment of High Blood Cholesterol in Adults
<0.001) respectively. Means NAFLD patients (Adults Treatment panel III) final report
may have more NASH like and severe disease circulation.2002 Dec17 106(25):3143-421.
6. Grundy SM ,cleeman JI , Danids SR , et al.
Conclusion Diagnosis and management of the
Non alcoholic fatty liver is the object of metabolic syndrome : An American Heart
significant scientific clinical interest which is association / National Heart , Lung and
going to increase in following years. Epidemiol- blood institute scientific statement ,
ogical studies demonstrate that NAFLD and circulation 2005oct 25 : 112(17) : 2735-52
metabolic syndrome are emerging as major 7. SanyalAJ . AGA Technical review on non
problems of public health. Our study also reveals alcoholic fatty liver disease
that there is higher prevalence of all the Gastroenteroloy 2002 ; 123 : 1705-25.
components of metabolic syndrome in cases of 8. Roti Agrawal ,sunita Mishra , VK Dixit &
NAFLD. Therefore whenever these parameters Sweta Rai. Association ofnon alcoholic
are encountered in the clinical setting, patients fatty liver disorder with obesity . Indian J
must be evaluated for the presence of NAFLD by PrevSoc med. 2008 ; 39 : 13-16.
abdominal ultrasonography. 9. Duseja Ajay, Das Ashim , Das Reena,
Early detection would help not only in modifying Dhiman RK, Chawla Y, BhansaliA,Kalra
the disease course and delaying its complications Naveen. The clinicopathological profile of
but would also play a major role in preventive indian patients with non alcoholic fatty
cardiology. liver disease(NAFLD) is different from
Acknowledgements and Disclosures: None that in the west.Dig dis Sci 2007
Statement of Interests: None Sep;52(9):2368-2374.
10. Uchida Deepa,Pipalia D, Chawla M, Patel
Reference R, Maniarsonali, Narayani Juneja Archana.
1. Bedogni G. MiglioliL.,Masutti F, Trilibeli Non-Alcoholic fatty liver disease
C, Merchesini G, Bellentani S, prevalence (NAFLD)- The Hepatic component of
and risk factor for non alcoholic fatty liver Metabolic syndrome.Jassoc Physicians
disease : the Dionysis nutrition and liver india 2009;57:201-204.
study. Hepatology . 2005july;42(1):44-52 11. Nomora H, KashiwagiS,Hayashi ,et al.
2. Angulo P. Non alcoholic fatty liver disease Prevalence of fatty liver in the general
NEngl J Med.2002apr18; 346(16):1221-31 population of Okinawa, Japan. Japanese
3. Adams LA,lymp JF . St Sauver Jet al the Journal of Medicine 1998; 27: 142-149.
natural history of nonalcoholic fatty liver 12. Singh SP, Nayak S , Swarn M ,et al.
disease: a population based cohort study. Prevalence of NAFLD in eastern coastal
Gastroenterology 2005(Jul);129(1):113- India-A Preliminary USG study. Tropical
121 Gastroenterology 2004; 2: 76 79.
4. Marchesini G, Brizi M, Bianchi G et al.
non alcoholic fatty liver disease a feature

Dr P.Asati et al JMSCR Volume 05 Issue 06 June 2017 Page 22904